Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections

An Open-label, Randomized Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabetic Inpatients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00044746

Enrollment

314

Registered

2002-09-06

Start date

2000-10-31

Completion date

2003-01-31

Last updated

2013-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Diabetic Foot

Keywords

Diabetes

Brief summary

Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.

Interventions

DRUGPiperacillin/Tazobactam

Study design

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with diabetes mellitus * Inpatient * Have 1 or more infected ulcer(s) below the ankle

Exclusion criteria

* Must not have gangrene or severely impaired arterial supply in your foot * Must not have a bone infection in the area of your ulcer * Must not have allergies to penicillins

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026